Walking around the 3D printing pioneer’s booth at Formnext, you could see the culmination of that with a busy, yet focused, set of applications and new products. “We’re taking a new approach now,” says Shell Haffner, 3D Systems’ Vice President, Product Management as he takes TCT on a guided tour of what’s new. There are plenty of new products to get to grips with, each with specific industries in-mind, and paired with software and materials, bolstering the “Application-focused strategy” 3D Systems’ CEO Jeff Graves shared in an interview with TCT towards the end of last year. Both well-established applications in the AM industry but 3D Systems hopes to bring a new level of productivity to that with the launch of another two machines, the DMP Flex 350 Dual and DMP Factory 350 Dual. Sticking with healthcare, while not necessarily new to 3D Systems, but no doubt debut to many visitors, was bioprinting. Since announcing its intention to invest in bioprinting and regenerative medicine back in January, 3D Systems has been working on applications in tissue engineering, human organs, and new drug therapies in partnership with United Therapeutics and CollPlant, and through the acquisition of Philadelphia-based developer of bioprinting solutions Allevi. “[Materials] opens up new applications, new customers, people that don’t even think about 3D printing right now, that’s exciting to me.
Read the full article at TCT Magazine
